24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
IFOSLIEVA 2 G is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | IFOSLIEVA 2 G |
|---|---|
| Composition | Ifosfamide for Injection with Mesna 2g |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
IFOSLIEVA 2 G (Ifosfamide for Injection with Mesna 2g) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
IFOSLIEVA 2 G (Ifosfamide for Injection with Mesna 2 g) is a prescription anticancer medicine used in the treatment of various solid tumors and hematological malignancies. It contains Ifosfamide 2 g, an alkylating chemotherapeutic agent, along with Mesna, a protective medicine that helps reduce the risk of urinary tract toxicity associated with Ifosfamide treatment. This combination is widely used in oncology to provide effective cancer management while enhancing patient safety.
Cancer develops when abnormal cells grow uncontrollably and invade healthy tissues. Ifosfamide works by damaging the DNA of rapidly dividing cancer cells, preventing them from multiplying and spreading throughout the body. By interfering with cancer cell replication, the medicine helps shrink tumors, slow disease progression, and improve treatment outcomes.
Mesna is included with Ifosfamide therapy because it helps protect the bladder from harmful metabolites produced during treatment. This additional protection plays a vital role in reducing the risk of hemorrhagic cystitis and other urinary complications commonly associated with alkylating chemotherapy agents.
IFOSLIEVA 2 G is commonly prescribed for:
The medicine may be administered alone or as part of combination chemotherapy protocols depending on the type of cancer, disease stage, and individual treatment requirements.
Manufactured under stringent pharmaceutical quality standards, IFOSLIEVA 2 G is designed to ensure consistent therapeutic performance, safety, and reliability. The injection should only be administered by qualified healthcare professionals experienced in oncology and chemotherapy treatment.
Patients receiving Ifosfamide therapy typically require regular monitoring through blood tests, kidney function assessments, liver function evaluations, urine analysis, and routine medical examinations to ensure safe and effective treatment.
Due to its broad anticancer activity and established role in modern chemotherapy protocols, IFOSLIEVA 2 G remains an important treatment option in oncology care worldwide.
IFOSLIEVA 2 G (Ifosfamide for Injection with Mesna 2 g) is primarily used for the treatment and management of various cancers.
The medicine is widely used in the treatment of soft tissue sarcomas affecting muscles, connective tissues, and other soft tissues.
Doctors may prescribe Ifosfamide as part of treatment protocols for certain bone cancers.
The medicine may be included in chemotherapy regimens for advanced or recurrent testicular cancer.
IFOSLIEVA may be used in selected ovarian cancer treatment programs.
The medicine can be included in specialized chemotherapy protocols for cervical cancer management.
Certain lung cancer treatment plans may incorporate Ifosfamide-based therapy.
The medicine may be used in selected lymphoma treatment regimens.
Ifosfamide is frequently combined with other anticancer medicines to improve treatment outcomes.
Ifosfamide belongs to a class of medicines known as Alkylating Agents.
IFOSLIEVA works by:
Mesna works simultaneously to:
This dual-action approach helps maximize treatment effectiveness while minimizing specific treatment-related complications.
Like all chemotherapy medicines, IFOSLIEVA 2 G may cause side effects in some patients. Side effects vary depending on dosage, treatment duration, and individual patient factors.
Patients may experience mild to moderate nausea after treatment.
Episodes of vomiting may occur during therapy.
Weakness and tiredness are commonly reported.
Temporary hair thinning or hair loss may occur.
Reduced appetite may affect nutritional intake.
Some patients may experience dizziness or lightheadedness.
Mild fever may occur during treatment.
Pain, redness, or irritation at the injection site may develop.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of IFOSLIEVA 2 G (Ifosfamide for Injection with Mesna 2 g) should always be determined by a qualified oncologist or healthcare professional.
Different cancers require different treatment schedules and protocols.
Dosage is commonly calculated according to body size.
Kidney health plays an important role in treatment planning.
Laboratory test results help determine treatment suitability.
Doctors may adjust therapy based on effectiveness and tolerability.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid possible drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is used for the treatment of various cancers including soft tissue sarcoma, bone sarcoma, testicular cancer, ovarian cancer, and certain lymphomas.
Ifosfamide is an alkylating chemotherapy medicine that damages cancer cell DNA and helps stop tumor growth.
Mesna helps protect the bladder from harmful metabolites produced during Ifosfamide treatment and reduces the risk of urinary complications.
Yes, it is a chemotherapy medicine widely used in oncology treatment programs.
Yes, the medicine may lower white blood cells, red blood cells, and platelets, requiring regular monitoring.
Adequate hydration helps support kidney function and assists in reducing treatment-related urinary complications.
Yes, doctors typically recommend blood tests, kidney function assessments, urine monitoring, and routine medical evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, chemotherapy, and cancer treatment.